We first compared different groups of CES2 expression and found that CCA patient groups with low (IRS = 0–3) or none (IRS = 0) tumoral CES2 immunoreactivity both had significantly shortened overall survival (p = 0.002, Fig. 3B; p = 0.006, Fig. 3C). This evidence concerns the gene CES2 and cholangiocarcinoma.